Improving Quality of Life for Allergic and Nonallergic Rhinitis Patients

Dr. Baroody mentioned that SAR is a worldwide phenomenon that has increased considerably in the past two decades. Patients whose symptoms remain uncontrolled with the usual medications should be treated with specific allergen immunotherapy.

He said that a Cochrane Collection review of SCIT for SAR identified 51 studies with a total of 2871 subjects who received treatment lasting from three days to three years. It showed that injection immunotherapy in suitably selected patients with SAR produced significant reductions in symptom severity, with a known and relatively low risk of serious adverse events.

©2007 The Triological Society